This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

P. Wolkenstein, MD
Department of Dermatology Hôpital Henri-Mondor 94010 Créteil Cedex, France

J. Revuz, MD
Créteil

J. C. Guillaume, MD
Colmar, France

M. F. Avril
Villejuif, France

O. Chosidow
Paris, France

Arch Dermatol. 1995;131(5):615-616.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We read with interest the case of ''Recurrence of Pemphigus Vulgaris Associated With Interleukin-2 Therapy'' reported by Prussick et al¹ in a recent issue of the ARCHIVES. Indeed, pemphigus vulgaris (PV) and various autoimmune disorders reported during interleukin-2 immunotherapy are diseases in which interleukin-2 might play a key role. Interestingly, these diseases are rare events during interleukin-2 immunotherapy, as discussed by Gaspari in his editorial.² In our own series of 25 patients with metastatic melanoma,³ we observed mucocutaneous lesions in 15% of 78 cycles of interleukin-2 infusion. Nine biopsy specimens were studied and did not reveal histologic or direct immunofluorescence patterns of autoimmune bullous skin diseases.

Nevertheless, we took a step toward Gaspari's ''unanswered questions'' concerning vitiligo and interleukin-2 therapy. Indeed, we had the opportunity to observe four cases of vitiligo in patients treated with interleukin-2 alone for metastatic melanoma out of our previous series of 25 . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?